Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Don't Forget Roche

Since it's not publicly listed on the major U.S. stock exchanges, Roche (OTC BB: RHHBY.PK) never gets its fair share of attention as the largest biopharma (by market capitalization). Yesterday the Swiss-based drugmaker announced its full-year 2007 results.

It was a good year for Roche. Thanks to its majority ownership of Genentech (NYSE: DNA  ) and European marketing rights to Avastin and several other top Genentech drugs, Roche got to ride on the coattails of Genentech's success last year. In 2007, overall sales growth was 10% in local currencies for Roche, or 15% sales growth if you use the sickly dollar as your measuring stick. Net income was up 25% year over year.

The majority of Roche's sales ($34 billion worth) occurred in its pharmaceuticals and biopharma drugs division, which saw the launch of anemia drug Mircera in Europe. Mircera is set to compete against Amgen's (Nasdaq: AMGN  ) Epogen in Europe and also received marketing approval in the U.S., but its U.S. launch has been held up by patent litigation from Amgen.

For 2008, Roche expects its top- and bottom-line growth to slow as a result of "significantly" higher research and development spending, and also because of a "significant" slowdown in sales of flu treatment Tamiflu. Roche's forecast is for high single-digit percentage sales growth for the year and earnings per share "at least" equal to 2007's levels.

Roche has an excellent drug pipeline and is looking more and more like the undisputed leader in treating diseases like hepatitis C. It has a ton of promising early and mid-stage antiviral compounds, a huge presence in oncology because of Genentech, and even second-generation diabetes drugs like its GLP-1 analogue and DPP-IV inhibitor.

While it may be a pain for U.S. investors to buy shares of Roche on the Pink Sheets, Roche's rich pipeline makes for a long-term outlook that's anything but painful.

Read/Post Comments (0) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 567446, ~/Articles/ArticleHandler.aspx, 10/24/2016 2:52:24 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,229.58 83.87 0.46%
S&P 500 2,151.02 9.86 0.46%
NASD 5,305.09 47.69 0.91%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/24/2016 2:36 PM
AMGN $158.45 Down -0.06 -0.04%
Amgen CAPS Rating: ****
DNA $94.97 Down +0.00 +0.00%
Genentech CAPS Rating: ****